Transition, Actinide, Or Lanthanide Metal Containing Patents (Class 424/9.42)
-
Publication number: 20080241072Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.Type: ApplicationFiled: March 25, 2008Publication date: October 2, 2008Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
-
Publication number: 20080233052Abstract: The present invention relates to particles comprising cores of tungsten or tungsten in mixture with other metallic elements wherein said cores are coated and have an average size of at least 20 nm. Further, the invention relates to pharmaceuticals containing such particles, and to the use of such pharmaceuticals specifically as contrast agents in diagnostic imaging, in particular in X-ray imaging of atherosclerotic plaque and liver tumours.Type: ApplicationFiled: May 19, 2006Publication date: September 25, 2008Inventor: Oskar Axelsson
-
Patent number: 7388024Abstract: The present invention provides indeno[2,1a]indene and isoindolo[2,1-a]indole derivatives of the Formula I, its salts and its stereoisomers, wherein X, R1, R2, R3, R4, R6, R7, R8, R9, R11, R12, R13 and R14 are as described in the specification. The invention also provides a method to prepare the compound of formula I, pharmaceutical composition containing such compounds, and method to manufacture a medicament. These compounds are useful in the treatment of various CNS disorders, hematological disorders, eating disorders, diseases associated with pain, respiratory diseases, genito-urological disorders, cardio vascular diseases and cancer.Type: GrantFiled: June 29, 2006Date of Patent: June 17, 2008Assignee: Suven Life Sciences LimitedInventors: Jasti Venkateswarlu, Satya Nirogi Ramakrishna Venkata, Sastri Kambhampati Rama, Shreekrishna Shirsath Vikas, Kandikere Vishwottam Nagaraj
-
Patent number: 7211241Abstract: Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging.Type: GrantFiled: October 17, 2003Date of Patent: May 1, 2007Assignee: Schering AktiengesellschaftInventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
-
Patent number: 7163935Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: June 3, 2003Date of Patent: January 16, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Patent number: 7138106Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: GrantFiled: June 5, 2002Date of Patent: November 21, 2006Assignee: Mirco Therapeutics, Inc.Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Patent number: 7122172Abstract: Disclosed are Drug Delivery Molecules (DDMs) which both facilitate functional imaging, as by PET or SPECT, and create a biological effect and methods of their use. These DDMs are variously designed to target specific receptors, then become internalized and then function biologically, as for purposes of cell destruction or therapy.Type: GrantFiled: September 9, 2002Date of Patent: October 17, 2006Inventor: Gerhart Graupner
-
Patent number: 7081452Abstract: Substituted 1,4,7-triazacyclononane-N,N?,N?-triacetic acid compounds with a pendant donor amino group, metal complexes thereof, compositions thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder.Type: GrantFiled: December 13, 2002Date of Patent: July 25, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Martin W. Brechbiel, Hyun-Soon Chong
-
Patent number: 6974567Abstract: Detectably labeled macrophage scavenger receptor antagonists useful for the diagnosis and monitoring of various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.Type: GrantFiled: August 14, 2003Date of Patent: December 13, 2005Assignee: Bristol-Myers Squibb Pharma CompanyInventors: David Scott Edwards, Shuang Liu
-
Patent number: 6827926Abstract: Metallotetrapyrrolic compounds having photherapeutic properties useful in photodetection and phototherapy of target issues, particularly porphyrins and azaporphyrins that including gallium in the central pyrrolic core. Also disclosed are methods of using metallotetrapyrrolic compounds for the treatment or detection of cardiovascular disease.Type: GrantFiled: May 31, 2002Date of Patent: December 7, 2004Assignee: Miravant Pharmaceuticals, Inc.Inventors: Byron C. Robinson, Ian M. Leitch, Stephanie Greene, Steve Rychnovsky
-
Patent number: 6797257Abstract: The present invention relates to a composition that includes gadolinium particles encapsulated in microsphere shells. The composition is suitable for use as a contrast agent with a plurality of imaging modalities, including, for example, ultrasound, magnetic resonance imaging, and computed temography. The compositions also are useful for therapeutic applications, including neutron capture therapy.Type: GrantFiled: October 12, 2001Date of Patent: September 28, 2004Assignee: The Board of Trustees of the University of IllinoisInventors: Michael A. McDonald, Kenneth L. Watkin
-
Publication number: 20040101479Abstract: A biopsy site marker comprises small bodies or pellets of gelatin which enclose substantially in their interior a radio (X-ray) opaque object. The gelatin pellets are deposited into the biopsy site, typically a cylindrical opening in the tissue created by the recent use of a vacuum assisted large core biopsy device, by an applicator device that includes an elongated cylindrical body that forms a flexible tube and a piston slidable in the tube. One end of the tube is placed into the biopsy site. Typically, several gelatin pellets, only some of which typically do, but all of which may contain the radio opaque object, are deposited sequentially into the site through the tube. The radio opaque objects contained in the gelatin bodies are of a non-biological configuration and readily identifiable as man-made object, so that in observation by typical mammography equipment they do not assume the shape of a line, whereby they are readily distinguishable from granules and lines of calcification.Type: ApplicationFiled: October 10, 2003Publication date: May 27, 2004Applicant: SenoRx, Inc.Inventors: Fred H. Burbank, Paul Lubock, Michael L. Jones, Nancy Forcier
-
Publication number: 20040092818Abstract: X-ray imageable articles, for instance surgical implements or parts therefore which are used in minimally invasive surgical procedures, may be prepared by a process including the steps of:Type: ApplicationFiled: November 4, 2003Publication date: May 13, 2004Applicant: Scimed Life Systems, Inc.Inventors: Timothy J. Weaver, Dion Mraz
-
Publication number: 20040047807Abstract: The present invention relates to the use of neurotoxic substances, which have a toxic effect in particular for the axon and the nociceptive nerve endings, for the preparation of an agent for the treatment of joint pain.Type: ApplicationFiled: August 11, 2003Publication date: March 11, 2004Inventor: Dominik Meyer
-
Patent number: 6689752Abstract: Compounds that modulate natural &bgr; amyloid peptide aggregation are provided. The modulators of the invention comprise a peptide, preferably based on a &bgr; amyloid peptide, that is comprised entirely of D-amino acids. Preferably, the peptide comprises 3-5 D-amino acid residues and includes at least two D-amino acid residues independently selected from the group consisting of D-leucine, D-phenylalanine and D-valine. In a particularly preferred embodiment, the peptide is a retro-inverso isomer of a &bgr; amyloid peptide, preferably a retro-inverso isomer of A&bgr;17-21. In certain embodiments, the peptide is modified at the amino-terminus, the carboxy-terminus, or both. Preferred amino-terminal modifying groups include cyclic, heterocyclic, polycyclic and branched alkyl groups. Preferred carboxy-terminal modifying groups include an amide group, an alkyl amide group, an aryl amide group or a hydroxy group.Type: GrantFiled: June 29, 2001Date of Patent: February 10, 2004Assignee: Praecis Pharmaceuticals, IncorporatedInventors: Mark A. Findeis, Malcolm L. Gefter, Gary Musso, Ethan R. Signer, James Wakefield, Susan Molineaux, Joseph Chin, Jung-Ja Lee, Michael Kelley, Sonja Komar-Panicucci, Christopher C. Arico-Muendel, Kathryn Phillips, Neil J. Hayward
-
Patent number: 6686458Abstract: The present invention features biarsenical molecules. Target sequences that specifically react with the biarsenical molecules are also included. The present invention also features kits that include biarsenical molecules and target sequences. Tetraarsenical molecules are also featured in the invention.Type: GrantFiled: April 19, 2002Date of Patent: February 3, 2004Assignee: The Regents of the University of CaliforniaInventors: Roger Y. Tsien, B. Albert Griffin
-
Patent number: 6676928Abstract: Perfluoroalkyl-containing complexes with polar radicals of general formula I (K)1-G-(Z-Rf)m(R)p (I) in which R means the polar radical, Rf means a perfluorinated carbon chain, K is a metal complex, and Z represents a linker group, are suitable for intravenous lymphography, for tumor diagnosis and for infarction and necrosis imaging.Type: GrantFiled: August 10, 2001Date of Patent: January 13, 2004Assignee: Schering AktiengesellschaftInventors: Johannes Platzek, Peter Mareski, Ulrich Niedballa, Bernd Raduechel, Hanns-Joachim Weinmann, Bernd Misselwitz
-
Publication number: 20030232017Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.Type: ApplicationFiled: December 11, 2002Publication date: December 18, 2003Inventors: Johannes Platzek, Heribert Schmitt-Willich, Heinz Gries, Gabriele Schuhmann-Giampieri, Hubert Vogler, Hanns-Joachim Weinmann, Hans Bauer
-
Patent number: 6660248Abstract: An contrast agent for therapeutic or diagnostic treatment comprises a fullerene scaffold and an iodinated moiety bonded to the scaffold. The agent may further comprise a water solubilizing moiety bonded to the scaffold, which may be a serinol malonodiamide, hydroxyl, and 1,3-diol. The fullerene scaffold may comprise an empty fullerene or an endohedral fullerene. A method for making the agent includes a) synthesizing iodinating moieties, b) protecting serinols, forming protected serinols, c) attaching the protected serinols to the iodinated moieties, forming iodinated serinols, d) attaching the iodinated serinols to the fullerene scaffold, and, optionally, d) de-protecting the serinols. Also disclosed are a method for providing diagnostic treatment to a patient comprising administering to said patient a radiopaque effective amount of a contrast agent comprising a fullerene scaffold and an iodinated moiety, a method of making a blood pool agent.Type: GrantFiled: November 9, 2001Date of Patent: December 9, 2003Assignee: William Marsh Rice UniversityInventors: Lon J. Wilson, John T. Wharton, Uri Sagman
-
Publication number: 20030206860Abstract: Disclosed is a medical device (5) and more particularly, an implantable biomaterial. The biomaterial comprises a radiopaque (22) collagenous biomaterial (10).Type: ApplicationFiled: December 19, 2001Publication date: November 6, 2003Inventors: Mark W. Bleyer, Michael C. Hiles, Umesh H. Patel
-
Publication number: 20030206858Abstract: Improved metal complex-containing pharmaceutical agents are described which, as an additive, contain one or more complexing agents and/or one or more weak metal complex(es) or mixtures thereof.Type: ApplicationFiled: June 16, 2003Publication date: November 6, 2003Applicant: Schering AGInventors: Heinz Gries, Ulrich Speck, Hanns-Joachim Weinmann, Hans Peter Niendorf, Wolfgang Seifert
-
Publication number: 20030185758Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: ApplicationFiled: March 24, 2003Publication date: October 2, 2003Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Publication number: 20030157027Abstract: Disclosed are methods for treating urinary incontinence in a mammal wherein a composition comprising a biocompatible polymer, a biocompatible solvent, and a contrast agent is delivered to the periurethral tissue of the mammal.Type: ApplicationFiled: December 30, 2002Publication date: August 21, 2003Inventors: George Wallace, Richard J. Greff
-
Patent number: 6596259Abstract: The present invention is directed to a complex comprising a redox-active metal cluster in a chemically inert shell. The inventive complex has the formula M8(&mgr;4-E)4(&mgr;-L)12X, where M is chosen from a transition metal, a lanthanide, an actinide and mixtures thereof; E is a chalcogenide; L is a bridging ligand; and X is a terminal ligand. The chemically inert shell enables the complex to exhibit structural stability over several oxidation states, and to exhibit reversible electrochemical reduction properties. A single reactor method of making this complex from simple starting materials is also disclosed. The active center further allows the octanuclear complex to be used in making supercluster assemblies that have electron transfer properties or in making contrasting agents for MRI applications, for example.Type: GrantFiled: December 22, 1999Date of Patent: July 22, 2003Assignee: University of Puerto RicoInventor: Raphael G. Raptis
-
Publication number: 20030099597Abstract: Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery.Type: ApplicationFiled: October 28, 2002Publication date: May 29, 2003Inventors: Thomas J. Whalen, Chinh N. Tran, Noah M. Roth, Richard J. Greff
-
Publication number: 20030086874Abstract: Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery.Type: ApplicationFiled: October 28, 2002Publication date: May 8, 2003Inventors: Thomas J. Whalen, Chinh N. Tran, Noah M. Roth, Richard J. Greff
-
Publication number: 20030003056Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: ApplicationFiled: August 20, 2002Publication date: January 2, 2003Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Publication number: 20020187102Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: ApplicationFiled: June 5, 2002Publication date: December 12, 2002Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Publication number: 20020164288Abstract: An contrast agent for therapeutic or diagnostic treatment comprises a fullerene scaffold and an iodinated moiety bonded to the scaffold. The agent may further comprise a water solubilizing moiety bonded to the scaffold, which may be a serinol malonodiamide, hydroxyl, and 1,3-diol. The fullerene scaffold may comprise an empty fullerene or an endohedral fullerene. A method for making the agent includes a) synthesizing iodinating moieties, b) protecting serinols, forming protected serinols, c) attaching the protected serinols to the iodinated moieties, forming iodinated serinols, d) attaching the iodinated serinols to the fullerene scaffold, and, optionally, d) de-protecting the serinols. Also disclosed are a method for providing diagnostic treatment to a patient comprising administering to said patient a radiopaque effective amount of a contrast agent comprising a fullerene scaffold and an iodinated moiety, a method of making a blood pool agent.Type: ApplicationFiled: November 9, 2001Publication date: November 7, 2002Inventors: Lon J. Wilson, John T. Wharton, Uri Sagman
-
Patent number: 6476069Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.Type: GrantFiled: January 29, 1999Date of Patent: November 5, 2002Assignee: Provasis Therapeutics Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6476070Abstract: A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: GrantFiled: February 2, 2000Date of Patent: November 5, 2002Assignee: Provasis Therapeutics Inc.Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6468502Abstract: The invention relates to new, monomeric, perfluoroalkyl-substituted metal complexes, processes for their production, and their use in diagnosis and therapy. The compounds according to the invention are suitable especially as in vivo contrast media in nuclear spin tomography (MRT). They can preferably be used as blood-pool agents and as lymphographic agents.Type: GrantFiled: November 8, 1999Date of Patent: October 22, 2002Assignee: Schering AktiengesellschaftInventors: Johannes Platzek, Ulrich Niedballa, Bernd Radüchel, Wolfgang Schlecker, Hanns-Joachim Weinmann, Thomas Frenzel, Bernd Misselwitz, Wolfgang Ebert
-
Patent number: 6461587Abstract: The invention relates to macrocyclic perfluoroalkylamides, their production and their use in diagnosis.Type: GrantFiled: March 22, 2000Date of Patent: October 8, 2002Assignee: Schering AktiengesellschaftInventors: Johannes Platzek, Ulrich Niedballa, Detlev Suelzle, Wolfgang Schlecker, Bernd Raduechel, Hanns-Joachim Weinmann, Thomas Frenzel, Bernd Misselwitz, Wolfgang Ebert
-
Patent number: 6447749Abstract: This invention describes galenical formulations that contain perfluoroalkyl-containing dye molecules and other perfluoroalkyl-containing substances. The new formulations are suitable as, i.a., contrast media for near-infrared diagnosis.Type: GrantFiled: September 29, 2000Date of Patent: September 10, 2002Assignees: Schering Aktiengesellschaft, Institut fuer DiagnostikforschungInventors: Kai Licha, Andreas Becker, Bjoern Riefke, Johannes Platzek
-
Patent number: 6426059Abstract: Cascade polmer complexes with at least 16 ions of an element of atomic numbers 20 to 29, 39, 42, 44 or 57-83, useful NMR or x-ray lymphography imaging.Type: GrantFiled: July 20, 2000Date of Patent: July 30, 2002Inventors: Heribert Schmitt-Willich, Johannes Platzek, Bernd Radüchel, Andreas Mühler, Thomas Frenzel
-
Publication number: 20020098150Abstract: A composition useful as an embolic agent that selectively creates an embolic blockage in the lumen of a blood vessel, duct, fistula or other like body passageways by combining a monomer component and a second component wherein, said monomer component comprises of a alkyl cyanoacrylate monomer and at least one inhibitor agent; and said second component that functions as an opacificant agent and a polymerization retardant.Type: ApplicationFiled: January 29, 1999Publication date: July 25, 2002Inventors: ROBERT E. KRALL, CHARLES W. KERBER, KIMBERLY KNOX
-
Patent number: 6413495Abstract: An X-ray-intercepting gold complex of mono-L-aspartyl (or mono-L-glutamyl) chlorin e6 or a salt thereof is used in the therapy of the tumor, cancer or arteriosclerosis lesions by X-ray irradiation. The complex provides a sharp x-ray image of tumor, solid cancer or lesions of arteriosclerosis. A similar platinum complex may also be utilized.Type: GrantFiled: January 10, 2001Date of Patent: July 2, 2002Assignee: Meiji Seika Kaisha, Ltd.Inventors: Katsuo Aizawa, Shinjiro Sumi, Hirotada Takahashi, Noriaki Aman, Yoshihiko Terayama, Shuichi Gomi
-
Publication number: 20020076381Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: ApplicationFiled: December 26, 2001Publication date: June 20, 2002Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Patent number: 6383470Abstract: The invention relates to microparticle preparations made of biodegradable copolymers for use in treatment and diagnosis, especially ultrasonic diagnosis, as well as a process for their production.Type: GrantFiled: July 21, 1997Date of Patent: May 7, 2002Inventors: Thomas Fritzsch, Dieter Heldmann, Werner Weitschies
-
Patent number: 6355275Abstract: Described are methods of embolization using an embolizing agent composition that includes microparticles with carbon surfaces, and comprising a contrast agent. Preferred microparticles include a permanently radiopaque particle substrate and a pyrolytic carbon surface.Type: GrantFiled: June 23, 2000Date of Patent: March 12, 2002Assignee: Carbon Medical Technologies, Inc.Inventor: Dean A. Klein
-
Publication number: 20020018752Abstract: The present invention provides compositions comprising a first component and a second component, wherein the first component includes at least two polymerizable organic monomers, and wherein the second component includes an oligomer of a polymerizable organic monomer, a plasticizer and an opacificant agent, wherein said composition polymerizes upon contact with an anionic environment. The compositions are useful for filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment. The composition are also useful for ablating diseased or undesired tissue by cutting off the blood supply to the tissue.Type: ApplicationFiled: May 23, 2001Publication date: February 14, 2002Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
-
Patent number: 6342202Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: GrantFiled: August 27, 1997Date of Patent: January 29, 2002Assignee: Micro Therapeutics, Inc.Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Patent number: 6335384Abstract: Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent. The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particular agent permits the agent to act as a structural lattice for the growing polymer precipitate. In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.Type: GrantFiled: October 10, 2000Date of Patent: January 1, 2002Assignee: Micro Therapeutics, Inc.Inventors: Scott Evans, John Perl, II, Richard Greff
-
Patent number: 6333110Abstract: Provided is a method of fluorescence imaging of living tissue using functionalized nanocrystals. The method comprises contacting an effective amount of functionalized nanocrystals with the living tissue; exposing the tissue to a spectrum of light suitable for exciting functionalized nanocrystals, present in fluorescently labeled tissue, to emit a emission spectrum comprising a fluorescence peak; and detecting any fluorescence peak emitted by the tissue exposed to the excitation spectrum of light, and obtaining a fluorescence image of the tissue. Also provided is a composition comprising a functionalized nanocrystal which is bound to a substrate in a living tissue.Type: GrantFiled: September 13, 1999Date of Patent: December 25, 2001Assignee: Bio-Pixels Ltd.Inventor: Emilio Barbera-Guillem
-
Patent number: 6319607Abstract: Provided are methods for purifying functionalized fluorescent nanocrystals having affinity ligand operably bound thereto by using a solid support matrix in a reactor through which solutions are circulated, and by using an immobilized solid phase formed by operably binding functionalized fluorescent nanocrystals to the solid support matrix. Also provided are purified functionalized fluorescent nanocrystals having affinity ligand operably bound thereto which are purified using the methods according to the present invention to be substantially free of free affinity ligand.Type: GrantFiled: June 8, 2000Date of Patent: November 20, 2001Assignee: Bio-Pixels Ltd.Inventors: Emilio Barbera-Guillem, Stephanie L. Castro
-
Patent number: 6309701Abstract: Provided are a fluorescent microsphere comprised of a plurality of fluorescent nanocrystals operably bound to a polymeric microsphere, and a method of producing the fluorescent microspheres which comprises contacting the polymeric microsphere with a plurality of fluorescent nanocrystals under suitable conditions in which the fluorescent naocrystals become operably bound to the polymeric microsphere. Also provided is a method of using the fluorescent microspheres capable of determining the presence or absence of a predetermined number of analytes in a sample by contacting the sample with the fluorescent microspheres, and detecting the fluorescence signal pattern of excited fluorescent microspheres bound to one or more analytes of the predetermined number of analytes, if present in the sample.Type: GrantFiled: May 24, 2000Date of Patent: October 30, 2001Assignee: Bio-Pixels Ltd.Inventor: Emilio Barbera-Guillem
-
Publication number: 20010024637Abstract: Disclosed are compositions suitable for use in embolizing blood vessels which compositions comprise a polymer, a biocompatible solvent and a contrast agent. The polymer is selected from the group consisting of polyacrylonitrile, polyurethane, polyvinylacetate, cellulose acetate butyrate, nitrocellulose and copolymers of urethane/carbonate and copolymers of styrene/maleic acid.Type: ApplicationFiled: May 4, 2001Publication date: September 27, 2001Inventors: Scott Evans, Richard J. Greff, James I. Wright
-
Patent number: 6287538Abstract: Chelate compounds of general formula I wherein X is a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-40, 42-44, 49 or 57-83, and Z1, Z2, R1, R2, R3 and R4 are as defined herein, as well as their salts with inorganic and/or organic bases, amino acids or amino acid amides, are valuable pharmaceutical agents, e.g., for NMR imaging.Type: GrantFiled: April 28, 1998Date of Patent: September 11, 2001Assignee: Schering AktiengesellschaftInventors: Heinz Gries, Erich Klieger, Bernd Radüchel, Heribert Schmitt-Willich, Hanns-Joachim Weinmann, Hubert Vogler, Gabriele Schuhmann-Giampieri, Jürgen Conrad
-
Patent number: 6281263Abstract: Disclosed are methods useful for treating vascular lesions wherein a non-particulate agent such as a metal coil is introduced into a vascular site (e.g., an aneurysm cavity) in conjunction with an embolizing composition comprising a biocompatible polymer and a biocompatible solvent. The biocompatible solvent is miscible or soluble in blood and also solubilizes the polymer during delivery. The biocompatible polymer is selected to be soluble in the biocompatible solvent but insoluble in blood. Upon contact with the blood, the biocompatible solvent dissipates from the embolic composition whereupon the biocompatible polymer precipitates. Precipitation of the polymer in the presence of the non-particulate agent permits the agent to act as a structural lattice for the growing polymer precipitate. In another embodiment, the biocompatible polymer composition can be replaced with a biocompatible prepolymer composition containing a biocompatible prepolymer.Type: GrantFiled: November 12, 1999Date of Patent: August 28, 2001Inventors: Scott Evans, John Perl, II, Richard Greff
-
Patent number: 6274121Abstract: Superparamagnetic particles consist of superparamagnetic one-domain particles and aggregates of superparamagnetic one-domain particles to whose surfaces are bound inorganic and optionally organic substances optionally having further binding sites for coupling to tissue-specific binding substances, diagnostic or pharmacologically active substances. The superparamagnetic particles consist of a mixture of small superparamagnetic one-domain particles with a particle size from 3 to 50 nm and stable, degradable aggregates of small superparamagnetic one-domain particles with a particle size from 10 to 1000 nm. They are made of iron hydroxyide, iron oxide hydrate, iron oxides, iron mixed oxides or iron to the surface of which are bound silicate group containing substances among the orthosilicic acids and their condensation products and phosphate-group containing substances among the ortho- or metaphosphoric acids and their condensation products. These substances may have further binding sites.Type: GrantFiled: April 27, 1999Date of Patent: August 14, 2001Inventor: Herbert Pilgrimm